Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia–Pacific region and Russia: Final results from the randomized C-CORAL study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 34, Issue 1, 2019, Pages 12-21

  Wei, Lai ^a   Jia, Ji Dong ^b   Wang, Fu Sheng ^c   Niu, Jun Qi ^d   Zhao, Xu Min ^e   Mu, Shengmei ^e   Liang, Li Wen ^e   Wang, Zaiqi ^e   Hwang, Peggy ^f   Robertson, Michael N ^f   Ingravallo, Paul ^f   Asante Appiah, Ernest ^f   Wei, Bo ^f   Evans, Barbara ^f   Hanna, George J ^f   Talwani, Rohit ^f   Duan, Zhong Ping ^g   Zhdanov, Konstantin ^h   Cheng, Pin Nan ⁱ   Tanwandee, Tawesak ^j   Nguyen, Van Kinh ^k   Heo, Jeong ^l   Isakov, Vasily ^m   George, Jacob ⁿ   more..

^a PEKING UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c BEIJING 302 HOSPITAL   (China)

^d JILIN UNIVERSITY   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f MERCK RESEARCH LABORATORIES   (United States)

^g CAPITAL MEDICAL UNIVERSITY   (China)

^h S M KIROV MILITARY MEDICAL ACADEMY   (Russian Federation)

ⁱ NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^j MAHIDOL UNIVERSITY   (Thailand)

^k National Hospital of Tropical Diseases   (Viet Nam)

^l Pusan National University School of Medicine   (South Korea)

^m FEDERAL RESEARCH CENTRE OF NUTRITION   (Russian Federation)

ⁿ UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

HCV clinical trials; HCV treatment; hepatitis C, clinical

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ELBASVIR; GRAZOPREVIR; HEMOGLOBIN; HEMOGLOBIN A1C; HEPATITIS B SURFACE ANTIGEN; VIRUS RNA; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; ELBASVIR-GRAZOPREVIR DRUG COMBINATION; IMIDAZOLE DERIVATIVE; NS3 PROTEIN, HEPATITIS C VIRUS; QUINOXALINE DERIVATIVE; VIRAL PROTEIN;

AMINOTRANSFERASE BLOOD LEVEL; ANKLE FRACTURE; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; AUSTRALIA; AUTOIMMUNE HEMOLYTIC ANEMIA; BODY MASS; CHINA; CHRONIC HEPATITIS C; CLINICAL OUTCOME; CONTROLLED STUDY; CONTUSION; CREATININE CLEARANCE; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FATIGUE; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; INTERACTIVE VOICE RESPONSE SYSTEM; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OUTCOME VARIABLE; PHASE 3 CLINICAL TRIAL; PLATELET COUNT; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; SAFETY; SOUTH KOREA; SUICIDE; SUSTAINED VIROLOGIC RESPONSE; TAIWAN; THAILAND; UPPER RESPIRATORY TRACT INFECTION; UTERUS BLEEDING; VIET NAM; ADULT; ANTIVIRAL RESISTANCE; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; ENZYMOLOGY; FAR EAST; GENETICS; GENOTYPE; HEPACIVIRUS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; AUSTRALIA; BENZOFURANS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; FAR EAST; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; QUINOXALINES; RUSSIA; SUSTAINED VIROLOGIC RESPONSE; THAILAND; VIETNAM; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 85058092561     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.14509     Document Type: Article

References (24)

1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 2014; 61: S45–S57.
2. Zepatier [summary of product characteristics]. Hoddesdon, Hertfordshire, UK: Merck Sharp & Dohme Ltd.; 2018.
3. Health Canada. Product Monograph Including Patient Medication Information: Zepatier. Kirkland, QC, Canada: Merck Canada Inc., 2017.
4. Zepatier [prescribing information]. Kenilworth, NJ: Merck & Co. Inc., 2018.
5. Coburn CA, Meinke PT, Chang W et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013; 8: 1930–1940.
6. Harper S, McCauley JA, Rudd MT et al. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med. Chem. Lett. 2012; 3: 332–336.
7. Summa V, Ludmerer SW, McCauley JA et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob. Agents Chemother. 2012; 56: 4161–4167.
8. Lahser FC, Bystol K, Curry S et al. The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob. Agents Chemother. 2016; 60: 2954–2964.
9. Liu R, Curry S, McMonagle P et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob. Agents Chemother. 2015; 59: 6922–6929.
10. Dore GJ, Altice F, Litwin AH et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann. Intern. Med. 2016; 165: 625–634.
11. Forns X, Gordon SC, Zuckerman E et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J. Hepatol. 2015; 63: 564–572.
12. Hezode C, Colombo M, Bourliere M et al. Elbasvir/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III study. Hepatology 2017; 66: 736–745.
13. Kwo P, Gane E, Peng CY et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 2017; 152: 164–175.e4.
14. Lawitz E, Gane E, Pearlman B et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385: 1075–1086.
15. Rockstroh JK, Nelson M, Katlama C et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015; 2: e319–e327.
16. Roth D, Nelson DR, Bruchfeld A et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015; 386: 1537–1545.
17. Sperl J, Horvath G, Halota W et al. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III randomized controlled trial. J. Hepatol. 2016; 65: 1112–1119.
18. Sulkowski M, Hezode C, Gerstoft J et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385: 1087–1097.
19. Zeuzem S, Ghalib R, Reddy KR et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann. Intern. Med. 2015; 163: 1–13.
20. Kumada H, Suzuki Y, Karino Y et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. J. Gastroenterol. 2017; 52: 520–533.
21. Zeuzem S, Serfaty L, Vierling J et al. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J. Gastroenterol. 2018; 53: 679–688.
22. George J, Burnevich EZ, Sheen IS et al. Efficacy in Asia-Pacific/Russian participants with chronic hepatitis C virus gentoype 1,4, or 5 infection. Hepatol. Commun. 2018; 2: 595–606.
23. Jin YJ, Lee JW, Lee JI et al. Multicenter comparison of PEG-IFN alpha2a or alpha2b plus ribavirin for treatment-naive HCV patient in Korean population. BMC Gastroenterol. 2013; 13: 74.
24. Liu CH, Liu CJ, Lin CL et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin. Infect. Dis. 2008; 47: 1260–1269.